Pulike Biological Engineering, Inc.

603566

CNE1000025N0

Pharmaceuticals

End-of-day quote Shanghai S.E. Other stock markets 06:00:00 2024-04-25 pm EDT			5-day change	1st Jan Change
17.2 ^CNY	-3.86%		-2.11%	-24.06%

Apr. 25	Pulike Biological Engineering, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
Apr. 25	Pulike Biological Engineering, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Tranche Update on Pulike Biological Engineering, Inc.'s Equity Buyback Plan announced on November 14, 2023.

January 02, 2024

From November 13, 2023 to December 31, 2023, the company has repurchased 359,000 shares, for CNY 7.64 million. With this, the company has completed the repurchase of 359,000 shares, for CNY 7.64 million under the buyback announced on November 14, 2023.

Latest news about Pulike Biological Engineering, Inc.

Pulike Biological Engineering, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	Apr. 25	CI
Pulike Biological Engineering, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Apr. 25	CI
Tranche Update on Pulike Biological Engineering, Inc.'s Equity Buyback Plan announced on November 14, 2023.	Mar. 31	CI
Tranche Update on Pulike Biological Engineering, Inc.'s Equity Buyback Plan announced on November 14, 2023.	Jan. 02	CI
Pulike Biological's Vaccine for Feline Respiratory Diseases Passes Chinese Emergency Evaluation	Dec. 07	MT
Pulike Biological Engineering, Inc. announces an Equity Buyback for CNY 120 million worth of its shares.	Nov. 13	CI
Pulike Biological Engineering, Inc. authorizes a Buyback Plan.	Nov. 12	CI
Pulike Biological Engineering, Inc. Reports Earnings Results for the Nine Months Ended September 30, 2023	23-10-15	CI
Pulike Biological Engineering, Inc.(XSSC:603566) added to S&P Global BMI Index	23-09-18	CI
Pulike Biological Engineering, Inc. Reports Earnings Results for the Half Year Ended June 30, 2023	23-08-29	CI
Pulike Biological Engineering, Inc. agreed to acquire Luoyang Lechong Health Technology Co., Ltd. from Shiji Mengbang Information Technology Co., Ltd. and Luoyang Jidi Biotechnology Center (Limited Partnership) for CNY 23.5 million.	23-06-30	CI
Pulike Biological Engineering Gets Certificate for Respiratory Drug for Chickens	23-05-08	MT
Pulike Biological Engineering, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-04-25	CI
Pulike Biological Engineering, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	23-04-25	CI
Frontier IP investee develops vaccine candidate for Streptococcus suis	22-12-02	AN
Pulike Biological Engineering, Inc. Reports Earnings Results for the Nine Months Ended September 30, 2022	22-10-25	CI
Pulike Biological Engineering Unit’s New Drug Wins Registration Certificate	22-10-19	MT
Pulike Biological Engineering, Inc. announced that it has received CNY 897.999976 million in funding from a group of investors	22-09-06	CI
Pulike Biological Engineering, Inc. Reports Earnings Results for the Half Year Ended June 30, 2022	22-08-09	CI
CAHIC ZENAQ Animal Pharmaceutical Co., Ltd announced that it expects to receive CNY 82.72 million in funding from China Animal Husbandry Industry Co., Ltd., Pulike Biological Engineering, Inc.	22-07-17	CI
Pulike Biological Engineering, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022	22-04-28	CI
Pulike Biological Engineering, Inc. Reports Earnings Results for the Full Year Ended December 31, 2021	22-04-28	CI
Pulike Biological Engineering, Inc. announced that it expects to receive CNY 900 million in funding from a group of investors	21-11-14	CI
Pulike Biological Engineering, Inc. Reports Earnings Results for the Nine Months Ended September 30, 2021	21-10-28	CI
Pulike Biological Engineering, Inc. Reports Earnings Results for the Half Year Ended June 30, 2021	21-07-29	CI

Chart Pulike Biological Engineering, Inc.

Duration

Period

Chart Pulike Biological Engineering, Inc.

More charts

Company Profile

Pulike Biological Engineering. Inc is principally engaged in the research, development, production and distribution of veterinary biological products and chemical medicines. The Company's veterinary biological products include vaccine and antibody, applied in the prevention and controlling of infection to epidemic disease for poultry and livestock. Its veterinary chemical medicines are mainly used in the treatment of epidemic diseases of poultry and livestock.

Sector

Pharmaceuticals

Calendar

2024-05-16 - Annual General Meeting

More about the company

Income Statement Evolution

More financial data

Ratings for Pulike Biological Engineering, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

17.2 CNY

Average target price

19.98 CNY

Spread / Average Target

+16.16%

Consensus

EPS Revisions

Estimates Revisions

Annual profits - Rate of surprise

Company calendar

Sector Veterinary Drugs

	1st Jan change	Capi.
PULIKE BIOLOGICAL ENGINEERING, INC.	-24.06%	805M
ZOETIS INC.	-19.73%	72.39B
ELANCO ANIMAL HEALTH INCORPORATED	-11.01%	6.54B
BLUESTAR ADISSEO COMPANY	+15.88%	3.43B
VIMIAN GROUP AB	-0.68%	1.4B
JINYU BIO-TECHNOLOGY CO., LTD.	-17.27%	1.34B
VETOQUINOL SA	-2.73%	1.26B
CHINA ANIMAL HUSBANDRY INDUSTRY CO., LTD.	-28.16%	1.2B
WUHAN KEQIAN BIOLOGY CO.,LTD	-14.67%	1.12B
TIANJIN RINGPU BIO-TECHNOLOGY CO.,LTD.	-5.37%	990M

Veterinary Drugs

Pulike Biological Engineering, Inc.

Equities

603566

CNE1000025N0

Pharmaceuticals

Tranche Update on Pulike Biological Engineering, Inc.'s Equity Buyback Plan announced on November 14, 2023.

Latest news about Pulike Biological Engineering, Inc.

Chart Pulike Biological Engineering, Inc.

Company Profile

Income Statement Evolution

Ratings for Pulike Biological Engineering, Inc.

Analysts' Consensus

EPS Revisions

Annual profits - Rate of surprise

Sector Veterinary Drugs